COMPLETED

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to learn if the areas of stressed cells in the retina correlate to areas of disease identified in standard imaging and whether the images are helpful to identify potential areas of concern before symptoms or disease occurs. The main question it aims to answer is: * to evaluate patterns of increased autofluorescence FPF in the setting of geographic atrophy Participants will undergo FPF imaging using the OcuMet Beacon system.

Official Title

Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration: New Insights From Multimodal Imaging

Quick Facts

Study Start:2024-04-16
Study Completion:2025-05-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06381596

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 50 years or older and may be either male or female of any race
  2. * Established diagnosis of GA due to AMD
  3. * GA characteristics: GA area of between 1.25 mm² and 23 mm², with seventy percent of eyes having GA area ranging from 2.5 mm2 to 17.5 mm2. GA may be unifocal or multifocal. GA may be subfoveal or extrafoveal, with twenty-five percent of eyes having subfoveal GA. The presence of concurrent peripapillary atrophy will not exclude subjects from participation
  4. * Willing to participate as evidenced by signing the written informed consent
  1. * Unable to tolerate ophthalmic imaging
  2. * Presence of neovascular AMD on OCT as confirmed by an ophthalmologist
  3. * Presence of significant media opacity preventing adequate retinal imaging
  4. * Presence of concurrent retinal disease which may confound assessment

Contacts and Locations

Principal Investigator

Mihai Mititelu, MD, MPH
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison

Study Locations (Sites)

Department of Ophthalmology and Visual Sciences
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: University of Wisconsin, Madison

  • Mihai Mititelu, MD, MPH, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-16
Study Completion Date2025-05-27

Study Record Updates

Study Start Date2024-04-16
Study Completion Date2025-05-27

Terms related to this study

Additional Relevant MeSH Terms

  • Geographic Atrophy
  • Age-Related Macular Degeneration